Fall 2025

Software Engineer Intern

Posted on 9/5/2024

Genesis Therapeutics

Genesis Therapeutics

51-200 employees

AI-driven drug discovery for pharmaceuticals

No salary listed

Burlingame, CA, USA

Hybrid

Category
Backend Engineering
Full-Stack Engineering
Software Engineering
Required Skills
Machine Learning
Requirements
  • A strong software engineer who will write code quickly and uphold our code quality standards
  • A deep thinker who reasons from first principles over pattern matching
  • Interested in learning about biochemistry and the drug development process
Responsibilities
  • Build and expand on tools for visualizing molecules and proteins, analyzing machine learning models, and managing complex chemical workflows
  • Work closely with machine learning engineers and medicinal chemists to develop and productionize new computational methods for molecular property prediction
  • Help scale our data infrastructure to handle billions of datapoints and thousands of parallel deep learning and molecular dynamics jobs

Genesis Therapeutics focuses on developing new medicines by using artificial intelligence in the drug discovery process. The company employs a method that combines 3D spatial graph modeling and advanced molecular simulation to identify potential drug candidates. This approach allows Genesis Therapeutics to explore new chemical spaces and discover novel protein targets, which can lead to important new medicines. The company primarily serves other biotech and pharmaceutical firms, exemplified by its partnership with Eli Lilly, which includes a significant financial deal. Unlike many competitors, Genesis Therapeutics operates on a business-to-business model, generating revenue through strategic partnerships and upfront payments, as well as potential future earnings based on the success of the drugs developed. The goal of Genesis Therapeutics is to accelerate the drug discovery process and bring new treatments to market more efficiently.

Company Size

51-200

Company Stage

Series B

Total Funding

$280.1M

Headquarters

Burlingame, California

Founded

2019

Simplify Jobs

Simplify's Take

What believers are saying

  • Partnership with NVIDIA enhances AI capabilities for drug discovery.
  • $200M Series B funding supports platform and pipeline expansion.
  • Named a 'Fierce 15' company, highlighting industry leadership.

What critics are saying

  • Competition from AI-driven companies like Insilico Medicine and Exscientia.
  • Over-reliance on partnerships may lead to financial instability.
  • Regulatory challenges could delay AI-generated drug approvals.

What makes Genesis Therapeutics unique

  • Genesis uses 3D spatial graph modeling for novel drug discovery.
  • The GEMS platform leverages physics-inspired AI for molecular design.
  • Genesis collaborates with major pharma companies like Eli Lilly and Gilead.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Competitive salary

Equity

Medical, dental, & vision insurance

401(k) program

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-2%

2 year growth

0%
Delaware Business Times
May 28th, 2025
Incyte aims to accelerate drug research with AI collaboration

Earlier this year, Incyte inked a deal with Genesis Therapeutics to use the biotech company's AI platform to develop small molecule medicines.

Fierce Biotech
Feb 20th, 2025
Incyte pens $885M biobucks AI pact to use Genesis' GEMS to develop new drugs

Incyte is sticking to its strategy this year of finding "early-stage, exotic stuff" - paying Genesis Therapeutics $30 million upfront to use the biotech's artificial intelligence platform to develop small molecule medicines against undisclosed targets.

Genetic Engineering & Biotechnology News
Dec 18th, 2024
Genesis Therapeutics Secures Nvidia Investment Boost

Nvidia’s venture arm, NVentures, has increased its investment in AI drug discovery firm Genesis Therapeutics. Genesis, founded by Evan Feinberg, has raised over $300 million, including a $200 million Series B in 2023. The collaboration aims to enhance Genesis' AI platform, GEMS, for drug discovery. Genesis is also working with Gilead, Eli Lilly, and Genentech on various projects. The company plans to expand its workforce beyond its current 80 employees.

Finsmes
Nov 14th, 2024
Genesis Therapeutics Receives Equity Investment From NVIDIA

Genesis Therapeutics receives equity investment from NVIDIA.

BioPharmaTrend
Nov 13th, 2024
Genesis Therapeutics, NVIDIA Partner; $200M Boost

Genesis Therapeutics has partnered with NVIDIA to enhance its AI platform, GEMS, for drug discovery. This collaboration is supported by additional funding from NVentures, NVIDIA's venture capital arm, following its participation in Genesis' $200 million Series B financing in August 2023. The partnership aims to optimize computational methods like equivariant neural networks to analyze complex 3D molecular structures, targeting diseases with high unmet needs and previously undruggable targets.

INACTIVE